Get Access to Elotuzumab in India

Elotuzumab is a speciality medication used in the management of Multiple Myeloma, a Haematological disorder. This drug has been given the breakthrough therapy status by the US FDA. Such designated drugs have significant role in the treatment of rare diseases and advanced conditions. Empliciti is the trade or brand name of this medication which is available as Empliciti 300mg and Empliciti 400mg. In Europe and US, this drug is commercially available, which is not the case in India. Therefore Elotuzumab in India is imported based on
specific patient needs

Empliciti was developed by Bristol-Myers Squibb and AbbVie, and is now commercially promoted by Bristol-Myers Squibb. The import possibilities for Empliciti in India are fulfilled from European countries like Germany. Going by the FDA approved indications, this drug is prescribed for Multiple Myeloma patients who have relapsed, those who underwent a prior treatment. In such cases, drugs like these are known to provide better outcomes and therefore it is always a genuine concern for the patients in India to seek import options.

Like many other chemotherapy or Haematology medications, Empliciti is a combination drug. The other medications that are to be given along with this drug are lenalidomide and dexamethasone. These two agents are available in India. There is another medication called Pomalyst, which can be offered instead of dexamethasone. Pomalyst is an option to import along with Empliciti in India.